Lonza Acquires Cell Discovery Technology Firm

Lonza says it has acquired Amaxa (Cologne, Germany), a technology supplier to the cell discovery market, for an undisclosed amount. The transaction is subject to anti-trust regulatory approval, which is expected to take place early in the third quarter, Lonza says. Amax provides high-end nucleic acid transfection systems and consumables to academic institutions and pharmaceutical and biotechnology businesses, Lonza says. Amaxa also has proprietary technologies in the niche transfection systems market. “Amaxa is an excellent fit with the Lonza Bioscience...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers